Ciclofilin药品授予专利在日本的亲环素抑制剂药物

StephenW

Ciclofilin Pharmaceuticals Granted Patent in Japan for Cyclophilin Inhibitor Drugs

February 24, 2015 09:00 ET | Source: Ciclofilin Pharmaceuticals Inc.

SAN DIEGO, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals, Inc. ("Ciclofilin" or the "Company"), a biotechnology company focused on the development of broad spectrum antivirals, today announced that the Company has been issued a patent in Japan for its cyclophilin inhibitor drugs entitled "Nonimmunosuppressive Cyclosporine Analogue Molecules."

The Company's lead molecule, CPI-431-32, is a candidate medicine that is designed to target and inhibit a host cellular enzyme known as cyclophilin A ("CyPA"). CyPA is responsible for activation of viral proteins critical for the life cycles of hepatitis B virus ("HBV"), human immunodeficiency virus type 1 ("HIV-1"), and hepatitis C virus ("HCV"). By understanding the nature of how cyclophilins play a role in viral replication, the Company has developed CPI-431-32, for the treatments of HBV, HIV-1, and HCV, as well as the treatment of infection with more than one of these viruses simultaneously (co-infection). Co-infection, in particular, represents an underserved, difficult-to-treat and unique patient population.

"Within the industrialized world, Japan has one of the highest rates of liver cancer linked directly to infection with HCV/HBV viruses," stated Dr. Cosme Ordoñez, Ciclofilin's President.  "The burden of HBV/HCV related liver cancers in the East Asia Region, including Japan, represents about 66% of the total number of patients suffering from this disease worldwide. Given the prevalence of these infections and co-infections in Japan, and the associated health care burden, we believe that our drug could potentially be an effective treatment for these diseases, especially in co-infected patients."
- See more at: http://globenewswire.com/news-re ... thash.rUmguNQE.dpuf

StephenW

Ciclofilin药品授予专利在日本的亲环素抑制剂药物

2015年2月24日09:00 ET |来源：Ciclofilin制药公司

SAN DIEGO，2015年2月24日（GLOBE NEWSWIRE） - Ciclofilin制药公司（“Ciclofilin”或“公司”），一家生物技术公司，专注于广谱抗病毒药物的开发，今天宣布，该公司已经发出在日本的专利其环素抑制剂药物的题为“Nonimmunosuppressive环孢菌素模拟分子”。

该公司的铅分子，CPI-431-32，是设计目标，抑制被称为亲环素A（“亲环素A”），一个宿主细胞酶的候选药物。亲环素A是负责活化病毒蛋白质为B型肝炎病毒的生命周期（“HBV”）关键的，人类免疫缺陷病毒1型（“HIV-1”），和丙型肝炎病毒（“HCV”）的。通过了解亲环是如何在病毒复制的作用的性质，本公司已开发CPI-431-32，乙肝，HIV-1和HCV的治疗，以及感染与一个以上的这些治疗同时病毒（合并感染）。共感染，特别是代表不足的，难以治疗和独特的患者群。

“在工业化国家，日本拥有的肝癌率最高的直接联系感染HCV / HBV病毒之一，”说科姆奥多涅斯博士，Ciclofilin总统。 “在东亚地区，包括日本在内的HBV / HCV相关的肝癌的主要负担，约占66％的患者这种疾病患的全球总人数的。鉴于这些感染和混合感染在日本的流行，和相关联的保健负担，我们相信，我们的药物可能是一种有效的治疗，这些疾病，尤其是在共同感染的患者“。
- 在查看更多： http://globenewswire.com/news-re ... Pharmaceuticals-Gra

重韧

小日本还是有研发能力的，就怕搞定了，它们也不说，军国主义的思想太厉害。

9病成医

hao2014

回复 重韧 的帖子

你想多了
就算火星人搞出来也行

战天斗hbv

回复 重韧 的帖子

日本科研还是蛮厉害的，受体抑制剂已经有候选化合物了，至少细胞体系有效，可以进入下一步了

咬牙硬挺

好消息

战天斗hbv

亲环素不指望，毒性问题有前车之鉴

newchinabok

好像现在是第二代，毒性小些吧，你想到，别人也想到了